Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible therapeutic vaccine platforms. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Investment Perspective

Scancell is an oncology-focussed clinical stage immunology specialist. It has two promising vaccine platforms, ImmunoBody and Moditope, and two antibody technologies, GlyMab (anti-glycans) and AvidiMab, with the potential to treat many solid cancers, either as monotherapy or in combination. Modi-1, the first Moditope programme, has started Phase I/II trials targeting hard-to-treat tumours. The lead ImmunoBody programme, SCIB1, is in a Phase II combination study in metastatic melanoma. The broad acting glycan antibodies are at earlier stages of development and will likely be partnered for clinical studies. AvidiMab technology will be increasingly employed to enhance avidity and potency, with the Phase I COVIDITY COVID-19 vaccine programme the most high-profile beneficiary. Our Scancell valuation, using a risk adjusted DCF model, is £237.4m, or 29.1p per share.

Market information

SymbolPrimary exchanges


FY22 results highlight clinical and corporate progress
Lighthouse | 28 Oct 2022
Optimum partner secured for first antibody deal
Lighthouse | 25 Oct 2022
First Moditope oncology vaccine enters the clinic
Lighthouse | 13 Jun 2022

Recent News

Dr Jean-Michel Cosséry appointed Chairman
01 Feb 2023
H123 interim results
25 Jan 2023
Vaccitech technology licenced to advance Modi-2
07 Nov 2022
First patient dosed in expansion phase of ModiFY
31 Oct 2022